Korro Bio, Inc. Debt Conversion, Converted Instrument, Amount
Korro Bio, Inc. (KRRO) reported Debt Conversion, Converted Instrument, Amount of $5.38 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2020-03-26
- Korro Bio, Inc. debt conversion, converted instrument, amount for fiscal 2018 was $5.38M, a 71.32% decline from fiscal 2017.
- Korro Bio, Inc. debt conversion, converted instrument, amount for fiscal 2017 was $18.74M.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2018-12-31 | $5.38M 10-K · filed 2020-03-26 |
| 2017-12-31 | $18.74M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |